This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Illumina (ILMN) Q3 Earnings Beat Estimates, '22 View Slashed
by Zacks Equity Research
Delays in instruments and consumables purchases, negative foreign exchange impact and consumables inventory deleveraging are expected to impede growth in the rest of 2022 for Illumina (ILMN).
Illumina (ILMN) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of 17.24% and 1.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Illumina (ILMN) Ahead of Earnings?
by Zacks Equity Research
Illumina (ILMN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
How Investors Can Grab Better Returns for Medical Using the Zacks ESP Screener
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Clene Inc. (CLNN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Clene Inc. (CLNN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Illumina (ILMN) in Q3 Earnings?
by Zacks Equity Research
The extended lockdown issues in limited geographies, including Greater China, where Illumina (ILMN) has extensive business, are expected to have adversely impacted its top line during the third quarter.
Illumina (ILMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $220.57, marking a +0.25% move from the previous day.
PacBio's (PACB) Latest Offering to Enhance Genome Sequencing
by Zacks Equity Research
PacBio's (PACB) latest sequencing panels are expected to simplify the study of the difficult-to-sequence or accurately map genomes, thereby aiding researchers.
Illumina (ILMN) Stock Moves -1.64%: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $199.32, marking a -1.64% move from the previous day.
Illumina (ILMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Illumina (ILMN) closed at $190.79, marking a -1.56% move from the previous day.
Illumina (ILMN) Stock Moves -1.61%: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $190.38 in the latest trading session, marking a -1.61% move from the prior day.
Illumina (ILMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed the most recent trading day at $199.88, moving -1.03% from the previous trading session.
Illumina (ILMN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Illumina (ILMN) closed at $210.35 in the latest trading session, marking a +1.47% move from the prior day.
Company News for Sep 7, 2022
by Zacks Equity Research
Companies In The News Are: BBBY, SGFY, CVS, LOW, ILMN.
Here is What to Know Beyond Why Illumina, Inc. (ILMN) is a Trending Stock
by Zacks Equity Research
Illumina (ILMN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Trending Stock Illumina, Inc. (ILMN) a Buy Now?
by Zacks Equity Research
Zacks.com users have recently been watching Illumina (ILMN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Stock Market News for Aug 16, 2022
by Zacks Equity Research
U.S. stock markets closed higher on Monday to start a new week on the back of a four-week winning streak.
Illumina (ILMN) Q2 Earnings Miss Estimates, Slashes '22 View
by Zacks Equity Research
Robust sales contribution across operating segments drove Illumina's (ILMN) Q2 top line.
Company News for Aug 15, 2022
by Zacks Equity Research
Companies In The News Are: ILMN, FLO, VIAV, AQN.
The Zacks Analyst Blog Highlights PepsiCo, Qualcomm, HSBC, Automatic Data Processing and Illumina
by Zacks Equity Research
PepsiCo, Qualcomm, HSBC, Automatic Data Processing and Illumina are part of the Zacks top Analyst Blog.
Illumina (ILMN) Q2 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Illumina (ILMN) delivered earnings and revenue surprises of -9.52% and 4.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Top Research Reports for PepsiCo, QUALCOMM & HSBC
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), QUALCOMM Incorporated (QCOM) and HSBC Holdings plc (HSBC).
Illumina Q2 Preview: 8th Consecutive EPS Beat in Store?
by Derek Lewis
Just in its latest quarter, ILMN registered a solid 23% bottom-line beat.
Celularity, Inc. (CELU) Q2 Earnings Beat Estimates
by Zacks Equity Research
Celularity, Inc. (CELU) delivered earnings and revenue surprises of 111.54% and 32.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?